UK Regulator Approves Merck KGaA Unit's Ogsiveo for Progressing Desmoid Tumors

MT Newswires · 6d ago
12:19 PM EST, 01/07/2026 (MT Newswires) -- The UK Medicines and Healthcare products Regulatory Agency on Wednesday approved Nirogacestat hydrobromide, or Ogsiveo, therapy for the treatment of adult patients with progressing desmoid tumors. The British regulator approved Ogsiveo under its International Recognition Procedure, with the European Medicines Agency as the reference regulator. The drug was developed by Merck KGaA (MRK.F) unit SpringWorks Therapeutics. Desmoid tumors are non-cancerous tumors that usually form in connective tissues in the arms, legs or abdomen, and can cause damage to nearby tissues.